Zhejiang Garden Biopharmaceutical Co.,Ltd. (SHE:300401)
China
· Delayed Price · Currency is CNY 13.21
+0.06 (0.46%)
Apr 29, 2026, 3:04 PM CST
SHE:300401 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 1,170 | 1,220 | 1,221 | 1,082 | 1,397 | 1,107 | Upgrade
|
| Other Revenue | 17.7 | 17.7 | 22.45 | 12.93 | 20.39 | 9.75 | Upgrade
|
| Revenue | 1,188 | 1,237 | 1,243 | 1,095 | 1,418 | 1,117 | Upgrade
|
| Revenue Growth (YoY) | -4.16% | -0.47% | 13.58% | -22.78% | 26.89% | 69.40% | Upgrade
|
| Cost of Revenue | 556.46 | 555.88 | 519.59 | 441.4 | 486.37 | 350.66 | Upgrade
|
| Gross Profit | 631.43 | 681.52 | 723.7 | 653.25 | 931.14 | 766.44 | Upgrade
|
| Selling, General & Admin | 220.69 | 234.8 | 308.87 | 378.77 | 444.55 | 257.61 | Upgrade
|
| Research & Development | 72.43 | 65.46 | 83.78 | 90.91 | 70.34 | 59.28 | Upgrade
|
| Other Operating Expenses | 21.96 | 18.51 | 13.24 | 16.44 | 16.24 | 3.48 | Upgrade
|
| Operating Expenses | 313.1 | 320.89 | 407.84 | 483.74 | 533.66 | 320.69 | Upgrade
|
| Operating Income | 318.33 | 360.63 | 315.86 | 169.51 | 397.48 | 445.75 | Upgrade
|
| Interest Expense | -31.91 | -32.47 | -35.63 | -38.41 | -21.82 | -10.81 | Upgrade
|
| Interest & Investment Income | 10.51 | 9.64 | 11.01 | 20.54 | 13.75 | 32.49 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.92 | -1.92 | 6.31 | 7.02 | 11.1 | -2.79 | Upgrade
|
| Other Non Operating Income (Expenses) | -16.38 | -0.69 | -0.35 | -0.3 | -0.65 | -0.19 | Upgrade
|
| EBT Excluding Unusual Items | 278.63 | 335.19 | 297.19 | 158.36 | 399.86 | 464.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.23 | 3.77 | 0.25 | -0.34 | -2.83 | 0.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.24 | -2.24 | 31.53 | -0.04 | 17.8 | 76.22 | Upgrade
|
| Asset Writedown | -3.97 | -3.98 | -0.44 | -0.22 | -1.01 | -0.09 | Upgrade
|
| Other Unusual Items | 22.01 | 19.76 | 30.17 | 53.27 | 28.67 | 48.38 | Upgrade
|
| Pretax Income | 297.67 | 352.5 | 358.69 | 211.04 | 442.48 | 589.37 | Upgrade
|
| Income Tax Expense | 39.05 | 47.64 | 49.48 | 18.7 | 58.76 | 75.42 | Upgrade
|
| Earnings From Continuing Operations | 258.62 | 304.86 | 309.21 | 192.35 | 383.72 | 513.94 | Upgrade
|
| Minority Interest in Earnings | 0.01 | 0.01 | 0 | - | - | -30.18 | Upgrade
|
| Net Income | 258.62 | 304.86 | 309.21 | 192.35 | 383.72 | 483.77 | Upgrade
|
| Net Income to Common | 258.62 | 304.86 | 309.21 | 192.35 | 383.72 | 483.77 | Upgrade
|
| Net Income Growth | -17.70% | -1.41% | 60.76% | -49.87% | -20.68% | 83.79% | Upgrade
|
| Shares Outstanding (Basic) | 550 | 544 | 542 | 550 | 548 | 544 | Upgrade
|
| Shares Outstanding (Diluted) | 603 | 598 | 595 | 601 | 548 | 544 | Upgrade
|
| Shares Change (YoY) | 4.71% | 0.53% | -1.07% | 9.65% | 0.85% | 7.38% | Upgrade
|
| EPS (Basic) | 0.47 | 0.56 | 0.57 | 0.35 | 0.70 | 0.89 | Upgrade
|
| EPS (Diluted) | 0.43 | 0.51 | 0.52 | 0.32 | 0.70 | 0.89 | Upgrade
|
| EPS Growth | -21.40% | -1.92% | 62.50% | -54.29% | -21.35% | 71.15% | Upgrade
|
| Free Cash Flow | 197.07 | 112.78 | -13.97 | -84.57 | -2.89 | -203.33 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | 0.19 | -0.02 | -0.14 | -0.01 | -0.37 | Upgrade
|
| Dividend Per Share | 0.113 | 0.113 | 0.114 | 0.071 | 0.140 | 0.188 | Upgrade
|
| Dividend Growth | -0.88% | -0.88% | 60.56% | -49.29% | -25.53% | 82.52% | Upgrade
|
| Gross Margin | 53.16% | 55.08% | 58.21% | 59.68% | 65.69% | 68.61% | Upgrade
|
| Operating Margin | 26.80% | 29.14% | 25.41% | 15.48% | 28.04% | 39.90% | Upgrade
|
| Profit Margin | 21.77% | 24.64% | 24.87% | 17.57% | 27.07% | 43.31% | Upgrade
|
| Free Cash Flow Margin | 16.59% | 9.11% | -1.12% | -7.72% | -0.20% | -18.20% | Upgrade
|
| EBITDA | 502.01 | 538.72 | 471.63 | 302.82 | 458.27 | 490.2 | Upgrade
|
| EBITDA Margin | 42.26% | 43.54% | 37.93% | 27.66% | 32.33% | 43.88% | Upgrade
|
| D&A For EBITDA | 183.67 | 178.09 | 155.77 | 133.31 | 60.79 | 44.45 | Upgrade
|
| EBIT | 318.33 | 360.63 | 315.86 | 169.51 | 397.48 | 445.75 | Upgrade
|
| EBIT Margin | 26.80% | 29.14% | 25.41% | 15.48% | 28.04% | 39.90% | Upgrade
|
| Effective Tax Rate | 13.12% | 13.52% | 13.80% | 8.86% | 13.28% | 12.80% | Upgrade
|
| Revenue as Reported | 1,188 | 1,237 | 1,243 | 1,095 | 1,418 | 1,117 | Upgrade
|
| Advertising Expenses | - | 3.11 | 2.37 | 0.97 | 0.7 | 0.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.